PuSH - Publication Server of Helmholtz Zentrum München

Huynh, D.* ; Winter, P.* ; Märkl, F.* ; Endres, S. ; Kobold, S.

Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.

Semin. Immunopathol. 45, 215-227 (2022)
Publ. Version/Full Text DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
The clinical use of cellular immunotherapies is gaining momentum and the number of approved indications is steadily increasing. One class of cellular therapies—chimeric antigen receptor (CAR)-modified T cells—has achieved impressive results in distinct blood cancer indications. These existing cellular therapies treating blood cancers face significant relapse rates, and their application beyond hematology has been underwhelming, especially in solid oncology. Major reasons for resistance source largely in the tumor microenvironment (TME). The TME in fact functionally suppresses, restricts, and excludes adoptive immune cells, which limits the efficacy of cellular immunotherapies from the onset. Many promising efforts are ongoing to adapt cellular immunotherapies to address these obstacles, with the aim of reshaping the tumor microenvironment to ameliorate function and to achieve superior efficacy against both hematological and solid malignancies.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Corresponding Author
Keywords Car-t Cells ; Cellular Immunotherapy ; Cytokine ; Inflammation ; Stroma ; Tumor Microenvironment; Chimeric Antigen Receptor; Car-t-cells; Fibroblast Activation Protein; Dendritic Cells; Cancer-immunotherapy; Immune Surveillance; Antitumor Efficacy; Phase-i; Therapy; Recognition
ISSN (print) / ISBN 1863-2297
Journal Seminars in Immunopathology
Quellenangaben Volume: 45, Issue: 2, Pages: 215-227 Article Number: , Supplement: ,
Publisher Springer
Publishing Place Berlin ; Heidelberg
Non-patent literature Publications
Institute(s) Unit for Clinical Pharmacology (KKG-EKLiP)
Grants
Marie-Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector Foundation
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
Melanoma Research Alliance Grants
Else Kroner-Fresenius-Stiftung
German Cancer Aid
Ernst-Jung-Stiftung
LMU Munich's Institutional Strategy LMUexcellent
Bundesministerium fur Bildung und Forschung
European Research Council
German Research Foundation (DFG)
Fritz-Bender Foundation
Wilhelm-Sander-Stiftung
Deutsche Jose-Carreras Leukamie Stiftung
Projekt DEAL

Go-Bio initiative